Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 15, 2021 9:54am
159 Views
Post# 34009079

RE:RE:RE:84 percent upside

RE:RE:RE:84 percent upside I have not seen the report either but he did give TH credit for a 25% chance of approval for NASH.

None of the analysts are giving any credit in their price targets for cancer but without data, they really cannot do so yet. I don't think the stock will be given much credit for cancer until the phase 1b results are in, assuming they show the drug actually works.

scarlet1967 wrote: I fully agree, I haven't seen the report but I bet despite positive comments about R&D programs there is very little or nothing priced in his analysis for any of the programs.
FredTheVoice wrote: Interesting,

But as other here mentionned, if cancer plateform is promising, 100% upside is just the very low of what we will see stock-wise.....

And what I think is that a lot of the board member here wont be able to enjoy the ride to 30$C......

FTV.




<< Previous
Bullboard Posts
Next >>